We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly (LLY) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
Wall Street analysts expect Eli Lilly (LLY - Free Report) to post quarterly earnings of $2.64 per share in its upcoming report, which indicates a year-over-year increase of 25.1%. Revenues are expected to be $9.83 billion, up 18.3% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 1.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Lilly metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Net Sales- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- Total' will reach $237.50 million. The estimate points to a change of +8.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- Immunology' should come in at $1.03 billion. The estimate indicates a year-over-year change of +10.7%.
The collective assessment of analysts points to an estimated 'Net Sales- Verzenio- Total' of $1.24 billion. The estimate indicates a year-over-year change of +34.1%.
Analysts expect 'Net Sales- Emgality (Galcanezumab) - Total' to come in at $156.80 million. The estimate indicates a year-over-year change of -7.4%.
The consensus estimate for 'Net Sales- Taltz (Ixekizumab / LY2439821 / IL-17) - US' stands at $492.12 million. The estimate indicates a year-over-year change of +4.2%.
Analysts forecast 'Net Sales- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- ROW' to reach $173.03 million. The estimate indicates a change of +2.9% from the prior-year quarter.
The average prediction of analysts places 'Net Sales- Taltz (Ixekizumab / LY2439821 / IL-17) - ROW' at $265.48 million. The estimate indicates a change of +14.6% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- US' will reach $64.47 million. The estimate points to a change of +26.9% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales- Jardiance (Empagliflozin/BI 10773) - ROW' should arrive at $360.36 million. The estimate indicates a year-over-year change of +27.7%.
The combined assessment of analysts suggests that 'Net Sales- Jardiance (Empagliflozin/BI 10773) - US' will likely reach $431.43 million. The estimate indicates a change of +11.7% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265) - ROW' will reach $370.11 million. The estimate suggests a change of -16.1% year over year.
Analysts' assessment points toward 'Net Sales- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265) - US' reaching $879.40 million. The estimate indicates a change of -35.9% from the prior-year quarter.
Over the past month, shares of Lilly have returned -12% versus the Zacks S&P 500 composite's -2.9% change. Currently, LLY carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Lilly (LLY) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Wall Street analysts expect Eli Lilly (LLY - Free Report) to post quarterly earnings of $2.64 per share in its upcoming report, which indicates a year-over-year increase of 25.1%. Revenues are expected to be $9.83 billion, up 18.3% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 1.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Lilly metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Net Sales- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- Total' will reach $237.50 million. The estimate points to a change of +8.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- Immunology' should come in at $1.03 billion. The estimate indicates a year-over-year change of +10.7%.
The collective assessment of analysts points to an estimated 'Net Sales- Verzenio- Total' of $1.24 billion. The estimate indicates a year-over-year change of +34.1%.
Analysts expect 'Net Sales- Emgality (Galcanezumab) - Total' to come in at $156.80 million. The estimate indicates a year-over-year change of -7.4%.
The consensus estimate for 'Net Sales- Taltz (Ixekizumab / LY2439821 / IL-17) - US' stands at $492.12 million. The estimate indicates a year-over-year change of +4.2%.
Analysts forecast 'Net Sales- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- ROW' to reach $173.03 million. The estimate indicates a change of +2.9% from the prior-year quarter.
The average prediction of analysts places 'Net Sales- Taltz (Ixekizumab / LY2439821 / IL-17) - ROW' at $265.48 million. The estimate indicates a change of +14.6% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- US' will reach $64.47 million. The estimate points to a change of +26.9% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales- Jardiance (Empagliflozin/BI 10773) - ROW' should arrive at $360.36 million. The estimate indicates a year-over-year change of +27.7%.
The combined assessment of analysts suggests that 'Net Sales- Jardiance (Empagliflozin/BI 10773) - US' will likely reach $431.43 million. The estimate indicates a change of +11.7% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265) - ROW' will reach $370.11 million. The estimate suggests a change of -16.1% year over year.
Analysts' assessment points toward 'Net Sales- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265) - US' reaching $879.40 million. The estimate indicates a change of -35.9% from the prior-year quarter.
View all Key Company Metrics for Lilly here>>>
Over the past month, shares of Lilly have returned -12% versus the Zacks S&P 500 composite's -2.9% change. Currently, LLY carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>